13F Holdings
中文EN

RNLXY Renalytix plc

Services-Medical Laboratories · OTC · SEC CIK 1811115 · Fiscal year ends 06/30

Financial factors as of 2024-03-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.2%
TTM net income YoY5.5%
TTM EPS YoY30.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-1.6%
Operating margin-1,531.6%
Net margin-1,687.8%
FCF margin—
EBITDA margin-1,515.1%

Returns

ROE-1,073.2%
ROA-154.4%
ROIC (approx.)—
Asset turnover0.09x

Leverage & solvency

Liabilities / assets226.7%
Debt / equity—
Current ratio0.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30FY20202020-06-30
Income statement
Revenue$2.29M$3.40M$2.97M$1.49M$0
Cost of revenue$2.13M$2.68M$2.10M$858,000$0
Gross profit$156,000$720,000$874,000$633,000$0
R&D expense$9.29M$14.30M$14.65M$10.04M$4.57M
SG&A expense$19.75M$28.66M$39.52M$23.48M$5.75M
Operating income-$29.61M-$42.22M-$53.18M-$31.92M-$10.31M
Pretax income-$33.45M-$45.60M-$45.25M-$35.34M-$9.84M
Income tax$4,000$2,000$25,000$0$0
Net income-$33.46M-$45.61M-$45.28M-$35.34M-$9.84M
EBITDA-$29.24M-$41.71M-$52.69M-$31.63M-$10.24M
EPS (basic)-0.31-0.55-0.62-0.49-0.17
EPS (diluted)-0.31-0.55-0.67-0.49-0.17
Weighted avg. shares (diluted)108.18M82.21M73.84M71.48M59.08M
Balance sheet
Cash & equivalents$4.68M$24.68M$41.33M$65.13M$13.29M
Short-term investments———$0$982,000
Receivables$722,000$776,000$901,000$594,000—
Current assets$6.12M$26.88M$44.75M$66.79M$14.84M
PP&E, net$216,000$1.03M$1.37M$2.49M$1.66M
Intangibles$869,000$1.05M$1.19M$1.23M—
Total assets$7.97M$30.63M$50.06M$78.58M$20.88M
Current liabilities$11.49M$16.14M$11.78M$7.06M$3.29M
Total liabilities$15.83M$23.66M$19.46M$7.12M$4.97M
Shareholders' equity-$7.85M$6.97M$30.61M$71.46M$15.91M
Shares outstanding154.37M93.78M74.76M72.20M59.42M
Cash flow statement
Operating cash flow-$30.11M-$34.09M-$45.92M-$28.40M-$9.52M
Capital expenditure—$0$557,000$773,000$804,000
Free cash flow—-$34.09M-$46.48M-$29.17M-$10.33M
Investing cash flow-$4,000$0-$662,000-$751,000-$1.17M
Financing cash flow$10.25M$16.39M$25.63M$77.24M$15.94M
Depreciation & amortization$364,000$508,000$489,000$282,000$70,000
Stock-based compensation$1.71M$2.93M$4.62M$2.66M$1.16M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.